webinar register page

Webinar banner
LILRB/ILT Syposium: Deep Dive into “Myeloid Checkpoint” Therapeutics in Cancer
Please join us for a virtual symposium focused on therapeutics targeting LILRB (also known as ILT) receptors, an emerging class of “myeloid checkpoints” in cancer. We are bringing together leaders in the field to discuss: 1) seminal literature establishing a role for these receptors in cancer, 2) emerging clinical data for Merck’s MK-4830 (LILRB2 antibody) as presented at ESMO 2020 and recently published in Clinical Cancer Research, 3) emerging clinical and preclinical therapeutic pipeline. Our symposium is timely as it follows and will include discussion of new data expected at AACR (April 8-13). It also precedes and thus serves as a preview for several clinical data updates anticipated throughout 2022.

Participating Panelists:
-Biond Biologics
Dr. Tehila Ben Moshe, Chief Executive Officer; Ilana Mandel – VP research and development

-Immune-Onc Therapeutics Inc.
Charlene Liao, PhD – President & Chief Executive Officer; Paul Woodard, MD – Chief Medical Officer

-Jounce Therapeutics (JNCE)
Rich Murray, PhD – Chief Executive Officer; Beth Trehu, MD– Chief Medical Officer

-NGM Biopharmaceuticals (NGM)
David Woodhouse, PhD – Chief Executive Officer; Siobhan Nolan Mangini – Chief Financial Officer

-Tizona Therapeutics
Courtney Beers, PhD – Chief Scientific Officer

-Experts - Dr. J. Bryan Iorgulescu and Dr. Chengcheng (Alec) Zhang


Hosted by Raymond James Biotech Analyst Steve Seedhouse | Steve.Seedhouse@RaymondJames.com

*Upon registration you’ll receive a confirmation email with your dial-in details. Please add to your Outlook calendar for easy access to the call.

02:59:00

* Required information
Loading
Register
“FOR INSTITUTIONAL USE ONLY”
All expressions of opinion reflect the judgment of the author(s) and are subject to change. This information should not be construed as a recommendation. The foregoing content is subject to change at any time without notice. Content provided herein is for informational purposes only. There is no guarantee that these statements, opinions or forecasts provided herein will prove to be correct. Economic and market conditions are subject to change. Raymond James & Associates, Inc., member New York Stock Exchange/SIPC.

Speakers

Dr. J. Bryan Iorgulescu
currently an Instructor at Brigham and Women's Hospital (Jul 2015-Present) and a Faculty Member at Harvard Medical School (Aug 2020-Present). He is also a Physician-Scientist at Dana-Farber Cancer Institute (Jul 2018-Present). Dr. Iorgulescu specializes in brain tumor immunology, molecular diagnostics, and clinical effectiveness. His clinical focus is the surgical and molecular pathology of cancer – in particular for CNS tumors. In the lab, Dr. Iorgulescu’s focus is on understanding the immunogenomics that underlie brain tumor pathogenesis and leveraging that understanding to develop biomarkers for immunotherapy response. Dr. Iorgulescu has co-authored more than 50 peer-reviewed manuscripts: including senior-author manuscripts in JAMA Oncology and Neuro-Oncology; co-authored manuscripts in Nature, Nature Medicine, and Cancer Cell; and co-first authored the Nature Reviews Clinical Oncology review of single-cell technologies for immuno-oncology.
Dr. Chengcheng (Alec) Zhang
Morton H. Sanger Professorship in Oncology and Michael L. Rosenberg Scholar for Biomedical Research @University of Texas Southwestern Medical Center
He received his postdoctoral training under the mentorship of Dr. Harvey Lodish at Whitehead Institute/MIT, where he initiated several projects on hematopoietic stem cells and cancer research. Dr. Zhang established his independent lab at UT Southwestern Medical Center in 2007. His laboratory research focuses on the biology of immune inhibitory receptors including leukocyte Ig-like receptor subfamily B (LILRB) in cancer immunology and hematopoietic cells. He is also accustomed to working at the intersection of basic research and its clinical applications; anti-LILRB2 and anti-LILRB4 blocking antibodies co-discovered by his team are in phase 1 clinical trials for treatment of solid tumors and myeloid leukemia. He published 110 peer-reviewed publications in hematopoietic stem cell and cancer research fields, including senior author publications in Nature, Nature Medicine, Nature Cancer, Nature Cell Biology, Nature Immunology, Cell Stem Cell, and Blood.

Share via Email

All fields are required
 

Switch Time Zone